Zivo Bioscience Reports Q3 Loss, Completes Private Placements

TL;DR

Zivo Bioscience lost $3.5M in Q3, but raised cash via private deals in Oct.

AI Summary

Zivo Bioscience, Inc. filed its Q3 2024 10-Q report on November 14, 2024, covering the period ending September 30, 2024. The company reported a net loss of $3,490,396 for the nine months ended September 30, 2024. During October 2024, Zivo Bioscience completed several private transactions, including a private placement with five individual investors and other private transactions, raising capital for its operations.

Why It Matters

This filing details Zivo Bioscience's financial performance and capital-raising activities, which are crucial for its ongoing operations and future development in the bioscience sector.

Risk Assessment

Risk Level: medium — The company reported a significant net loss, indicating potential financial instability and reliance on future funding.

Key Numbers

• $3.49M — Net Loss (For the nine months ended September 30, 2024, indicating operational expenses exceeding revenue.)
• $25.0M — Authorized Shares (Indicates the potential for future equity financing.)
• $0.001 — Par Value (Per share of common stock, typical for many publicly traded companies.)

Key Players & Entities

• Zivo Bioscience, Inc. (company) — Filer of the 10-Q report
• 20240930 (date) — End of the reporting period
• $3,490,396 (dollar_amount) — Net loss for the nine months ended September 30, 2024
• 20241114 (date) — Filing date of the 10-Q
• Five Individual Investors (company) — Participants in a private transaction

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ZIVO OTCQB Warrants to p
• $172,670 — ptember 30, 2024, the Company exchanged $172,670 in accounts payable to related parties
• $400,000 — n stock for an accrued bonus payable of $400,000 to the Company's CEO (see NOTE 5 - STOC
• $95,977 — tember 30, 2024, the Company recognized $95,977 in directors compensation expense for t
• $1.20 — ing stock price on December 29, 2023 of $1.20 per share . The value of the shares g

Filing Documents

• zivo_10q.htm (10-Q) — 771KB
• zivo_ex311.htm (EX-31.1) — 14KB
• zivo_ex312.htm (EX-31.2) — 11KB
• zivo_ex321.htm (EX-32.1) — 5KB
• zivo_ex322.htm (EX-32.2) — 5KB
• 0001654954-24-014463.txt ( ) — 3503KB
• zivo-20240930.xsd (EX-101.SCH) — 38KB
• zivo-20240930_lab.xml (EX-101.LAB) — 209KB
• zivo-20240930_cal.xml (EX-101.CAL) — 35KB
• zivo-20240930_pre.xml (EX-101.PRE) — 173KB
• zivo-20240930_def.xml (EX-101.DEF) — 105KB
• zivo_10q_htm.xml (XML) — 497KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 3 Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 3 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 25 Item 4.

Controls and Procedures

Controls and Procedures 25

- OTHER INFORMATION

PART II - OTHER INFORMATION 28 Item 1.

Legal Proceedings

Legal Proceedings 28 Item 1A.

Risk Factors

Risk Factors 28 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 28 Item 3. Defaults upon Senior Securities 28 Item 4. Mine Safety Disclosures 28 Item 5. Other Information 28 Item 6. Exhibits 29 2 Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

- Financial Statements

Item 1 - Financial Statements ZIVO BIOSCIENCE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEET (UNAUDITED) September 30, December 31, 2024 2023 ASSETS CURRENT ASSETS: Cash $ 159,403 $ 274,380 Accounts receivable 27,794 3,735 Prepaid expenses 249,348 147,262 Total current assets 436,545 425,377 OTHER ASSETS: Operating lease - right of use asset 22,305 98,280 Security deposit 36,739 32,058 Total other assets 59,043 130,338 TOTAL ASSETS $ 495,587 $ 555,715 CURRENT LIABILITIES: Accounts payable $ 787,599 $ 993,090 Accounts payable – related party 136,261 172,670 Customer deposits 45,000 - Current portion of long-term operating lease 22,027 106,342 Convertible debentures payable 240,000 240,000 Loan Payable 115,014 - Accrued interest 102,481 100,686 Accrued liabilities – employee bonus 1,130,274 1,148,770 Total current liabilities 2,578,656 2,761,558 LONG TERM LIABILITIES: - - TOTAL LIABILITIES 2,578,656 2,761,558 COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY (DEFICIT): Common stock, $ 0.001 par value, 25,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 3,490,396 and 2,382,356 issued and outstanding at September 30, 2024, and December 31, 2023, respectively 3,490 2,382 Additional paid-in capital 133,278,605 121,373,488 Accumulated deficit ( 135,365,164 ) ( 123,581,713 ) Total stockholders' equity (deficit) ( 2,083,069 ) ( 2,205,843 ) TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) $ 495,587 $ 555,715 See accompanying notes to unaudited condensed consolidated financial statements. 3 Table of Contents ZIVO BIOSCIENCE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) For the Three Months ended September 30, 2024 For the Three Months ended September 30, 2023 For the Nine Months ended September 30, 2024 For the Nine Months

View Full Filing

View this 10-Q filing on SEC EDGAR